跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Management of chemotherapy-induced hepatitis B virus reactivation
Yi Hsiang Huang
*
, Han Chieh Lin
, Shou Dong Lee
*
此作品的通信作者
臨床醫學研究所
研究成果
:
Review article
›
同行評審
15
引文 斯高帕斯（Scopus）
總覽
指紋
指紋
深入研究「Management of chemotherapy-induced hepatitis B virus reactivation」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Hepatitis B Surface Antigen (HBsAg)
100%
Chemotherapy-induced
100%
Hepatitis B Virus Reactivation
100%
Anti-HBc
60%
Cancer Patients
40%
Hepatitis B Virus
40%
Chemotherapy
40%
Viral Load
40%
Viral Reactivation
40%
Resolved Hepatitis B
40%
In Cancer
20%
Rituximab
20%
Chemotherapeutic Regimens
20%
All Cancer
20%
Hepatitis B Core-related Antigen
20%
Lymphoma Patients
20%
Antiviral Treatment
20%
Hepatic Decompensation
20%
Reverse Seroconversion
20%
Hepatitis Flare
20%
Viral Status
20%
Antiviral Prophylaxis
20%
Cytotoxic Chemotherapy
20%
Hepatitis B Virus Marker
20%
Medicine and Dentistry
Hepatitis B Virus
100%
Virus Reactivation
100%
Hepatitis B Antigen
71%
Hepatitis B Core Antibody
57%
Malignant Neoplasm
28%
Hepatitis B
28%
Chemotherapy
28%
Seroconversion
14%
Antivirus Agent
14%
Antiviral Therapy
14%
Decompensated Liver Cirrhosis
14%
Rituximab
14%
Cytotoxic Chemotherapy
14%
Immunology and Microbiology
Hepatitis B Virus
100%
Virus Reactivation
100%
HBsAg
71%
Hepatitis B Antigen
71%
Hepatitis B Core Antibody
57%
Hepatitis B
28%
Viral Load
28%
Seroconversion
14%
Rituximab
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis B Virus
100%
Chemotherapy
100%
Hepatitis B Antigen
71%
Hepatitis B Core Antibody
57%
Malignant Neoplasm
28%
Antivirus Agent
28%
Hepatitis B
28%
Rituximab
14%
Decompensated Liver Cirrhosis
14%
Cytotoxic Chemotherapy
14%